Red Hill Biopharma files Bekinda (RBH 102) with MHRA for European approval for treatment of Chemotherapy Nausea and Vomiting
RedHill Biopharma Ltd. an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that it has submitted a Marketing Authorization Application to the UK Medicines and Healthcare Products Regulatory Agency (�MHRA�) and several other member states seeking European marketing approval of RHB-102 for cancer patients suffering from chemotherapy and radiotherapy-induced nausea and vomiting (�CINV� and �RINV� respectively). RHB-102, newly branded as Bekinda, is a proprietary, oral, extended-release, once-daily pill formulation of the antiemetic drug ondansetron.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.